Open innovation networks between academia and industry: an imperative for breakthrough therapies

被引：106

作者：

Melese, Teri ^{[1
]}

Lin, Salima M. ^{[2
]}

Chang, Julia L. ^{[2
]}

Cohen, Neal H. ^{[1
,3
]}

机构：

[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[2] IBM Corp, Global Business Serv, Armonk, NY 10504 USA

[3] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA USA

来源：

关键词：

CONFLICTS-OF-INTEREST; TECHNOLOGIES; SCIENCE; TIME;

D O I：

10.1038/nm0509-502

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：502 / 507

页数：6

共 25 条

[1] The biomarkers consortium: On the critical path of drug discovery
Altar, C. A.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 361 - 364
[2] BERNSTEIN K, 2006, BIOCENTURY, V14, pA1
[3] RNAi technologies: a screen whose time has arrived
Blow, Nathan
[J]. NATURE METHODS, 2008, 5 (04) : 361 - 366
[4] Health industry practices that create conflicts of interest - A policy proposal for academic medical centers
Brennan, TA
Rothman, DJ
Blank, L
Blumenthal, D
Chimonas, SC
Cohen, JJ
Goldman, J
Kassirer, JP
Kimball, H
Naughton, J
Smelser, N
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (04): : 429 - 433
[5] Carpenter Siri, 2007, Science, V317, P966, DOI 10.1126/science.317.5840.966
[6] Chesbrough H., 2003, OPEN INNOVATION
[7] Chesbrough H., 2006, OPEN BUSINESS MODELS
[8] Open innovation and strategy
Chesbrough, Henry W.
Appleyard, Melissa M.
[J]. CALIFORNIA MANAGEMENT REVIEW, 2007, 50 (01) : 57 - +
[9] Integrating molecular medicine into the US health-care system: Opportunities, barriers, and policy challenges
Deverka, P. A.
Doksum, T.
Carlson, R. J.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (04) : 427 - 434
[10] Gordon M., 2007, POINT DEAL NEGOTIATE